Monopar Therapeutics Inc.
MNPRHealthcare|Biotechnology|US
$71.42
+4.20 (+6.25%)
DCF Value
$7.99
Tangible Book / Share
$15.32
Cash / Share
$15.72
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06617169 Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | Solid Tumor, Adult, Bladder Cancer | P1 | Active | 12 | Open-label | MNPR-101-PCTA-177Lu |
| NCT06337084 Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | Solid Tumor, Adult, Bladder Cancer | P1 | Active | 12 | Open-label | MNPR-101-DFO*-89Zr |
| NCT04648020 Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. | Chemoradiotherapy-Induced Severe Oral Mucositis | P2P3 | Terminated | 190 | RCT, Double-blind | Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet |
| NCT05043649 Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Advanced Soft-tissue Sarcoma | P1 | Terminated | 14 | Open-label | Camsirubicin |
| NCT06980506 MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer | Cancer, Solid Tumor | TEMPORARILY_NOT_AVAILABLE | — | — | — | |
| NCT06980519 MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer | Cancer, Solid Tumor | TEMPORARILY_NOT_AVAILABLE | — | — | MNPR-101-PCTA-177Lu |